The BPCA works by offering a six-month extension of patent exclusivity to drug manufacturers who conduct and submit pediatric studies requested by the Food and Drug Administration (FDA). This extension applies to all formulations of the drug, including those used by adults. The extra marketing time can be highly valuable, providing a strong incentive for companies to invest in pediatric research.
